SWP
VRTX icon

Strategic Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Strategic Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Sell
4,784
-274
-5% -$121K 0.15% 101
2026
Q1 		$2.26M Buy
5,058
+498
+11% +$232K 0.16% 102
2025
Q4 		$2.07M Sell
4,560
-483
-10% -$208K 0.14% 111
2025
Q3 		$1.98M Buy
5,043
+23
+0.5% +$9.61K 0.15% 103
2025
Q2 		$2.23M Buy
+5,020
New +$2.31M 0.18% 97
2024
Q4 		$1.7M Buy
3,680
+479
+15% +$222K 0.14% 111
2024
Q3 		$1.49M Buy
3,201
+294
+10% +$141K 0.14% 117
2024
Q2 		$1.36M Buy
2,907
+54
+2% +$23.4K 0.14% 116
2024
Q1 		$1.19M Buy
2,853
+460
+19% +$194K 0.13% 119
2023
Q4 		$974K Buy
2,393
+294
+14% +$109K 0.12% 129
2023
Q3 		$730K Sell
2,099
-45
-2% -$15.7K 0.1% 172
2023
Q2 		$754K Buy
2,144
+12
+0.6% +$4.04K 0.1% 171
2023
Q1 		$672K Buy
2,132
+174
+9% +$52.2K 0.1% 152
2022
Q4 		$565K Buy
+1,958
New +$597K 0.11% 159
2021
Q2 		– Sell
-2,514
Closed -$540K – 261
2021
Q1 		$540K Buy
2,514
+1,487
+145% +$327K 0.22% 115
2020
Q4 		$243K Buy
+1,027
New +$236K 0.1% 160
2018
Q2 		– Sell
-113
Closed -$18K – 837
2018
Q1 		$18K Hold
113
– – 0.01% 387
2017
Q4 		$17K Buy
+113
New +$16.7K 0.01% 381

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Strategic Wealth Partners's VRTX Position: Q2 2026 in Review

Strategic Wealth Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 5.4% in Q2 2026, selling an estimated $121K and leaving 4,784 shares worth $2.38M. The position accounts for 0.15% of the portfolio, ranked #101.

Strategic Wealth Partners first reported a position in VRTX in Q4 2017 and has held it in 18 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Strategic Wealth Partners held 4,784 shares of Vertex Pharmaceuticals worth $2.38M as of Q2 2026.
  • Strategic Wealth Partners sold 274 Vertex Pharmaceuticals shares in Q2 2026, an estimated $121K.
  • Vertex Pharmaceuticals made up 0.15% of Strategic Wealth Partners's portfolio in Q2 2026, its #101 holding.
  • Strategic Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 18 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Strategic Wealth Partners's 13F filing for Q2 2026, filed 12 Aug 2026.